基于生物信息学分析的潜在炎症性肠病标志物的挖掘及其免疫相关性
Yuwen Zhu1, Yanbin Pan1, Lichao Fan1
1Department of Anorectal Surgery, Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China.
Translational cancer research
|September 12, 2024
概括
研究人员确定了关键基因 (TIMP1,GUCA2B,HIF1A) 作为炎症性肠病 (IBD) 的潜在治疗生物标志物. 这些核心基因可能会为IBD患者带来新的治疗方法.
科学领域:
- 基因组学就是基因组学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 全球炎症性肠病 (IBD) 的发病率正在上升.
- IBD呈现出一种慢性,复发的过程,有效治疗生物标志物有限.
- 由于疾病的复杂性和缺乏向治疗方法,目前的治疗方法面临挑战.
研究的目的:
- 确定可以作为炎症性肠病 (IBD) 治疗生物标志物的关键核心基因.
- 发现新的分子标,以改善IBD管理.
- 为IBD治疗策略提供一个新的视角.
主要方法:
- 权重基因共同表达网络分析 (WGCNA) 用于识别与IBD相关的基因模块.
- 最小绝对收缩和选择操作员 (LASSO) 逻辑回归被用于选候选基因.
- 使用独立数据集和人工神经网络分析验证了Hub基因.
主要成果:
- 确定了12个显著的基因模块,其中5个模块与IBD密切相关.
- 三个核心基因TIMP1,GUCA2B和HIF1A被确定为潜在的枢纽基因.
- 这些枢纽基因在区分IBD组织与健康对照时表现出高精度 (AUC=0.946).
结论:
- TIMP1,GUCA2B和HIF1A被确定为IBD病变发生过程中的关键核心基因.
- 这些基因代表了IBD患者有前途的治疗点.
- 这些发现为开发更有效的IBD治疗提供了新的途径.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
324
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
324
Inflammatory Bowel Disease I: Ulcerative Colitis
153
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
153
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Inflammatory Bowel Disease II: Crohn's Disease
201
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
201
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


